文献速递妇科肿瘤

一种用于子宫内膜癌疑似患者筛查与快速分诊的简易宫颈阴道表观遗传学检测:在多个队列与病例对照集中的验证

A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets.
PubMed 文献 · J Clin Oncol · 2022-08-24

研究开发并验证了一种基于宫颈涂片、阴道拭子和自采样本的三标志物DNA甲基化检测WID-qEC,用于疑似子宫内膜癌女性的分诊。在症状患者中,宫颈涂片、自采和阴道拭子样本的敏感性分别为97.2%、90.1%和100%,特异性分别为75.8%、86.7%和89.1%。该检测在诊断前1年内的样本中识别出90.9%的子宫内膜癌病例。

要点

  • WID-qEC是一种基于GYPC和ZSCAN12基因区域DNA甲基化的三标志物非侵入性检测。
  • 在症状患者中,宫颈涂片样本敏感性97.2%、特异性75.8%;自采样本敏感性90.1%、特异性86.7%。
  • 检测性能在不同绝经状态、年龄、分期、分级、种族和组织学类型间相似。

核心结论

  • WID-qEC是一种非侵入性可靠检测,可用于有子宫内膜癌症状女性的分诊。
  • 由于可自采样本,该检测可能改善早期诊断并减少对当面就诊的依赖。

研究设计与样本

  • 研究开发阶段使用726份宫颈涂片样本(来自有和无子宫内膜癌的女性)。
  • 验证阶段使用562份宫颈阴道样本,涵盖三种采集方法(宫颈涂片n=248、阴道拭子n=63、自采n=251)和四种设置(病例对照n=388、绝经后出血队列n=63、Lynch综合征高风险女性队列n=25、筛查队列嵌套病例对照及诊断前最多3年样本n=86)。

主要发现

  • 在症状患者的宫颈涂片样本中,WID-qEC检测子宫内膜癌的敏感性为97.2%(95% CI,90.2至99.7),特异性为75.8%(95% CI,63.6至85.5)。
  • 在症状患者的自采样本中,敏感性为90.1%(95% CI,83.6至94.6),特异性为86.7%(95% CI,79.3至92.2)。
  • 在症状患者的阴道拭子样本中,敏感性为100%(95% CI,63.1至100),特异性为89.1%(95% CI,77.8至95.9)。
  • WID-qEC在诊断前最多1年的样本中识别出90.9%(95% CI,70.8至98.9)的子宫内膜癌病例。
  • 检测性能在不同绝经状态、年龄、分期、分级、种族和组织学类型间相似。

关键数值与推荐

  • WID-qEC为三标志物检测,评估GYPC和ZSCAN12基因区域的DNA甲基化。
  • 在症状患者宫颈涂片样本中,敏感性97.2%(95% CI,90.2至99.7),特异性75.8%(95% CI,63.6至85.5)。
  • 在症状患者自采样本中,敏感性90.1%(95% CI,83.6至94.6),特异性86.7%(95% CI,79.3至92.2)。
  • 在症状患者阴道拭子样本中,敏感性100%(95% CI,63.1至100),特异性89.1%(95% CI,77.8至95.9)。
  • 在诊断前最多1年的样本中,WID-qEC识别出90.9%(95% CI,70.8至98.9)的子宫内膜癌病例。

临床怎么用

  • WID-qEC可用于有子宫内膜癌症状女性的分诊。
  • 由于支持自采样本,该检测可能改善早期诊断并减少对当面就诊的依赖。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Endometrial cancer (EC) incidence has been rising over the past 10 years. Delays in diagnosis reduce survival and necessitate more aggressive treatment. We aimed to develop and validate a simple, noninvasive, and reliable triage test for EC to reduce the number of invasive diagnostic procedures and improve patient survival. METHODS: We developed a test to screen and triage women with suspected EC using 726 cervical smear samples from women with and without EC, and validated the test in 562 cervicovaginal samples using three different collection methods (cervical smear: n = 248; vaginal swab: n = 63; and self-collection: n = 251) and four different settings (case/control: n = 388; cohort of women presenting with postmenopausal bleeding: n = 63; a cohort of high-risk women with Lynch syndrome: n = 25; and a nested case/control setting from a screening cohort and samples taken up to 3 years before EC diagnosis: n = 86). RESULTS: We describe the Women's cancer risk IDentification - quantitative polymerase chain reaction test for Endometrial Cancer (WID-qEC), a three-marker test that evaluates DNA methylation in gene regions of GYPC and ZSCAN12. In cervical, self-collected, and vaginal swab samples derived from symptomatic patients, it detected EC with sensitivities of 97.2% (95% CI, 90.2 to 99.7), 90.1% (83.6 to 94.6), and 100% (63.1 to 100), respectively, and specificities of 75.8% (63.6 to 85.5), 86.7% (79.3 to 92.2), and 89.1% (77.8 to 95.9), respectively. The WID-qEC identified 90.9% (95% CI, 70.8 to 98.9) of EC cases in samples predating diagnosis up to 1 year. Test performance was similar across menopausal status, age, stage, grade, ethnicity, and histology. CONCLUSION: The WID-qEC is a noninvasive reliable test for triage of women with symptoms suggestive of ECs. Because of the potential for self-collection, it could improve early diagnosis and reduce the reliance for in-person visits.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Herzog C, Marín F, Jones A, et al. A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets. J Clin Oncol. 2022. PMID: 36001862. doi:10.1200/JCO.22.00266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。